Impaired angiotensin II signaling in septic shock
- PMID: 38877367
- PMCID: PMC11178728
- DOI: 10.1186/s13613-024-01325-y
Impaired angiotensin II signaling in septic shock
Abstract
Recent years have seen a resurgence of interest for the renin-angiotensin-aldosterone system in critically ill patients. Emerging data suggest that this vital homeostatic system, which plays a crucial role in maintaining systemic and renal hemodynamics during stressful conditions, is altered in septic shock, ultimately leading to impaired angiotensin II-angiotensin II type 1 receptor signaling. Indeed, available evidence from both experimental models and human studies indicates that alterations in the renin-angiotensin-aldosterone system during septic shock can occur at three distinct levels: 1. Impaired generation of angiotensin II, possibly attributable to defects in angiotensin-converting enzyme activity; 2. Enhanced degradation of angiotensin II by peptidases; and/or 3. Unavailability of angiotensin II type 1 receptor due to internalization or reduced synthesis. These alterations can occur either independently or in combination, ultimately leading to an uncoupling between the renin-angiotensin-aldosterone system input and downstream angiotensin II type 1 receptor signaling. It remains unclear whether exogenous angiotensin II infusion can adequately address all these mechanisms, and additional interventions may be required. These observations open a new avenue of research and offer the potential for novel therapeutic strategies to improve patient prognosis. In the near future, a deeper understanding of renin-angiotensin-aldosterone system alterations in septic shock should help to decipher patients' phenotypes and to implement targeted interventions.
Keywords: Angiotensin II; Angiotensin-converting enzyme; Circulatory failure; Dipeptidyl peptidase 3; Neprilysin; Renin–angiotensin–aldosterone system; Sepsis; Septic shock.
© 2024. The Author(s).
Conflict of interest statement
The Cardiovascular Markers in Stress Conditions (MASCOT) Research Group is supported by a research grant from 4TEEN4 Pharmaceuticals GmbH, which allowed salary support for two co-authors (AP, MG). AM received speaker’s honoraria from Abbott, Novartis, Orion, Roche, and Servier, and fees as a member of the advisory board and/or steering committee from Cardiorentis, Adrenomed, MyCartis, Neurotronik, and Sphingotec. PP received travel and consultancy reimbursement from Adrenomed, SphingoTec, 4TEEN4, AM-Pharma, Baxter, and EBI. The remaining authors have nothing to disclose.
Figures




Similar articles
-
Alterations in the renin-angiotensin system during septic shock.Ann Intensive Care. 2025 Mar 24;15(1):40. doi: 10.1186/s13613-025-01463-x. Ann Intensive Care. 2025. PMID: 40126750 Free PMC article.
-
The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.Trials. 2024 Mar 12;25(1):182. doi: 10.1186/s13063-024-07995-0. Trials. 2024. PMID: 38475822 Free PMC article.
-
The alternative renin-angiotensin system in critically ill patients: pathophysiology and therapeutic implications.Crit Care. 2023 Nov 20;27(1):453. doi: 10.1186/s13054-023-04739-5. Crit Care. 2023. PMID: 37986086 Free PMC article. Review.
-
Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock.Semin Cardiothorac Vasc Anesth. 2021 Mar;25(1):67-73. doi: 10.1177/1089253220949070. Epub 2020 Aug 12. Semin Cardiothorac Vasc Anesth. 2021. PMID: 32787515
-
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Pharmacol Res. 2017 Nov;125(Pt A):57-71. doi: 10.1016/j.phrs.2017.05.020. Epub 2017 May 29. Pharmacol Res. 2017. PMID: 28571891 Free PMC article. Review.
Cited by
-
Alterations in the renin-angiotensin system during septic shock.Ann Intensive Care. 2025 Mar 24;15(1):40. doi: 10.1186/s13613-025-01463-x. Ann Intensive Care. 2025. PMID: 40126750 Free PMC article.
-
Early multimodal vasopressor strategy in septic shock (TRICYCLE)-Study protocol for a randomized controlled clinical trial.PLoS One. 2025 Aug 29;20(8):e0331304. doi: 10.1371/journal.pone.0331304. eCollection 2025. PLoS One. 2025. PMID: 40880376 Free PMC article.
-
Clinical Outcomes of Angiotensin II Therapy in Vasoplegic Shock: A Systematic Review and Meta-Analysis.Life (Basel). 2024 Aug 29;14(9):1085. doi: 10.3390/life14091085. Life (Basel). 2024. PMID: 39337869 Free PMC article. Review.
-
Higher circulating ACE2 and DPP3 but reduced ACE and angiotensinogen in hyperreninemic sepsis patients.Clin Sci (Lond). 2025 Jan 15;139(1):43-53. doi: 10.1042/CS20242168. Clin Sci (Lond). 2025. PMID: 39699964 Free PMC article.
-
Targeting high circulating dipeptidyl peptidase 3 in circulatory failure.Crit Care. 2025 Jul 31;29(1):340. doi: 10.1186/s13054-025-05545-x. Crit Care. 2025. PMID: 40745610 Free PMC article. Review.
References
-
- Schweda F, Kurtz A. Regulation of renin release by local and systemic factors. Rev Physiol Biochem Pharmacol. 2011;161:1–44. - PubMed
Publication types
LinkOut - more resources
Full Text Sources